8-K: Dogwood Secures Royalty-Free SP16 License for Cancer Pain

Dogwood Therapeutics has acquired an exclusive, royalty-free global license for Serpin Pharma's SP16, an LRP1 agonist for chemotherapy-induced peripheral neuropathy, in an all-stock transaction.

Summary

• Dogwood Therapeutics (DWTX) entered into an Exclusive Licensing Agreement with Serpin Pharma Inc. and Rejuvenation Labs, Inc. (collectively, Serpin) for SP16, an intravenous formulation.
• The license is exclusive, worldwide, paid-up, and royalty-free, covering the development and commercialization of SP16 for cancer-related pain, including chemotherapy-induced peripheral neuropathy (CIPN).
• As consideration, Dogwood issued 382,034 shares of its common stock and 179.1878 shares of Series A-2 Non-Voting Convertible Preferred Stock to Serpin Pharma and Rejuvenation Labs.
• Tungsten Advisors, as financial advisor, received 10.8694 shares of Series A-2 Preferred Stock.
• The Series A-2 Preferred Stock converts into 10,000 shares of common stock per preferred share upon stockholder approval, subject to a 19.9% beneficial ownership limitation.
• Serpin, Tungsten affiliates, and Sealbond Limited (a holder of 211,383 common shares) have entered into support agreements to vote in favor of stockholder approvals required for the conversion of preferred stock and other matters.
• The National Cancer Institute (NCI) is fully funding a forthcoming Phase 1b CIPN study for SP16 IV, with patient enrollment projected to begin in the first half of 2026.
• Dogwood's lead candidate, Halneuron, a NaV1.7 inhibitor for chemotherapy-induced neuropathic pain (CINP), is in Phase 2b development, with interim data from 90-100 patients expected in December 2025.

Sentiment

Score: 8

Explanation: The acquisition of a royalty-free, NCI-funded clinical asset significantly strengthens the pipeline and de-risks early development, while the all-stock transaction preserves cash. The potential for synergy with the existing lead candidate is a strong positive. Dilution is a factor, but the strategic benefits appear to outweigh it, especially given the NCI funding.

Positives

• Secured an exclusive, worldwide, royalty-free license for SP16, expanding the company's pipeline in cancer-related pain.
• The SP16 IV Phase 1b CIPN study is fully funded by the National Cancer Institute, reducing immediate capital requirements for clinical development.
• SP16, a first-in-class LRP1 agonist, demonstrates both anti-inflammatory and neural repair activity, offering a potentially synergistic mechanism with Halneuron.
• The all-stock transaction preserves Dogwood's cash reserves, which is crucial for a clinical-stage biotechnology company.
• The license includes an irrevocable and perpetual option for Dogwood to convert license rights to irrevocable rights for $100,000, providing long-term security.
• Dogwood retains ownership of any improvements, modifications, or derivative works developed from the Licensed Technology.

Negatives

• The issuance of common and preferred stock to Serpin and Tungsten dilutes existing shareholders, representing 7.31% of the company's common stock on a fully diluted basis.
• Stockholder approval is required for the conversion of the Series A-2 Preferred Stock into common stock, introducing a potential point of uncertainty.
• The company's common stock listing and price could be impacted by the Licensing Agreement and the ability to successfully develop and commercialize SP16, as noted in forward-looking statements.

Risks

• The continued listing of common stock on Nasdaq is subject to risks.
• The impact of the Licensing Agreement on the price of common stock is uncertain.
• Ability to successfully develop and commercialize SP16 is not guaranteed.
• The company's actual results, levels of activity, performance, or achievements may differ materially from forward-looking statements due to known and unknown risks and uncertainties.
• The Series A-2 Preferred Stock conversion is subject to a beneficial ownership limitation, which could restrict a holder's ability to convert all shares at once.

Future Outlook

Dogwood Therapeutics aims to advance SP16 into clinical development for chemotherapy-induced peripheral neuropathy (CIPN), with a Phase 1b study fully funded by the National Cancer Institute expected to begin patient enrollment in the first half of 2026. The company also anticipates interim data from its Halneuron Phase 2b CINP study in December 2025 and final data in Q2/Q3 2026. The strategic goal is to deepen commitment to CIPN/CINP treatment and potentially expand into the broader cancer-related pain market, exploring synergistic effects between SP16 and Halneuron.

Management Comments

• "The SP16 in-license aligns with our strategic objective of expanding our research pipeline in an area where Dogwood’s pain and neuropathy management research expertise can add value to both the asset increasing our equity value for shareholders." Greg Duncan, Dogwood Therapeutics CEO
• "The National Cancer Institute’s funding of the SP16 IV Phase 1b program obviates the need to use our existing capital in the near-term to advance SP16 into clinical development." Greg Duncan, Dogwood Therapeutics CEO
• "After reviewing potential partners for this program, we believe Greg Duncan and the Dogwood team is best poised to take SP16 IV for cancer related pain through the clinic to address this major unmet need." Dr. Cohava Gelber, CEO of Serpin Pharma
• "SP16 IV may have intrinsic potential to deliver adjunctive improvement of non-pain symptoms if utilized with Halneuron, the Company’s lead development candidate." Lawrence Steinman, MD, Professor of Neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford University and Scientific Advisory Board Member of Serpin Pharma
• "Expanding a biotech company’s quality shots on goal is always valued, but doing so with two development candidates that stand on their own merit, with additional potential to be mechanistically synergistic, adds additional value to this exciting worldwide SP16 license." Mike Gendreau, M.D., Ph.D., Dogwood Therapeutics Chief Medical Officer
• "We intend to explore the potential of SP16, both as a treatment for a multitude of CIPN symptoms, as well as its potential to help with repair and/or restoration of nerve function damaged by chemotherapy." Mike Gendreau, M.D., Ph.D., Dogwood Therapeutics Chief Medical Officer

Industry Context

This licensing agreement positions Dogwood Therapeutics to address a significant unmet medical need in cancer-related pain, particularly chemotherapy-induced peripheral neuropathy (CIPN). The market for CINP is estimated at $1.5 billion. The NCI's full funding of the SP16 Phase 1b study underscores the high unmet need and the potential of SP16's novel LRP1 agonist mechanism. The strategy of combining SP16's neuroprotective and anti-inflammatory properties with Halneuron's analgesic effects could offer a comprehensive treatment approach, potentially differentiating Dogwood in a competitive pain management landscape where non-opioid solutions are highly sought after.

Comparison to Industry Standards

• The NCI's full funding of the SP16 Phase 1b study is a strong external validation of the asset's potential, a rare and highly favorable outcome for early-stage clinical programs, indicating significant scientific merit and unmet need.
• The royalty-free nature of the license is highly advantageous compared to typical biotech licensing deals, which often involve upfront payments, milestones, and tiered royalties, significantly improving the long-term profitability potential for Dogwood.
• The combination of SP16 (LRP1 agonist for neuroprotection/anti-inflammation) and Halneuron (NaV1.7 inhibitor for pain) represents a multi-modal approach to CIPN/CINP, which is a more comprehensive strategy than single-target therapies often pursued by competitors in the pain space.
• The estimated $1.5 billion CINP market indicates a substantial commercial opportunity, comparable to other high-value specialty pharmaceutical markets, making the acquisition of a promising candidate in this area strategically sound.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential dilution from the issuance of common stock and convertible preferred stock. However, the acquisition of a promising, NCI-funded asset could enhance long-term value. Stockholder approval is required for preferred stock conversion.
• **Employees**: The expansion of the pipeline with SP16 could lead to increased research and development activities, potentially creating new opportunities.
• **Customers (Patients)**: The addition of SP16 to the pipeline, especially with its potential synergy with Halneuron, offers hope for more effective treatments for cancer-related pain and chemotherapy-induced neuropathy, addressing a significant unmet medical need.
• **Serpin Pharma/Rejuvenation Labs**: Become significant shareholders in Dogwood Therapeutics and gain a partner for the development and commercialization of SP16.
• **Tungsten Advisors**: Received equity compensation for their financial advisory role, aligning their interests with Dogwood's success.
• **National Cancer Institute (NCI)**: Their funding of the SP16 Phase 1b study demonstrates confidence in the program and supports public health initiatives.

Next Steps

• Dogwood to file a Form S-3 registration statement for the resale of issued shares as soon as practicable, but no later than December 1, 2025.
• Dogwood expects to file a proxy statement with the SEC for stockholder approvals related to preferred stock conversion and other proposals.
• A special stockholder meeting is contemplated for Q4 2025 to vote on preferred share conversions.
• Dogwood plans to file an Investigational New Drug (IND) application for SP16 in Q4 2025.
• Patient enrollment for the NCI-funded SP16 IV Phase 1b CIPN study is projected to begin in the first half of 2026.
• Interim data from the Halneuron Phase 2b CINP study (90-100 patients) is projected in December 2025.
• Final data for the 200-patient Halneuron Phase 2b CINP study is projected in Q2/Q3 2026.
• Dogwood will assume sole responsibility for regulatory oversight, filings, and approvals for SP16 after Serpin transfers the IND application following the Phase 1b study.

Key Dates

Recommendation

The acquisition of the SP16 license is a significant positive development. The royalty-free nature of the license, coupled with the National Cancer Institute's full funding of the initial Phase 1b study, substantially de-risks the early development of a promising asset in a high-need area. This strategic move expands the company's pipeline, offers potential synergy with the existing lead candidate Halneuron, and preserves cash through an all-stock transaction. While dilution is a consideration, the long-term value creation potential from a de-risked, NCI-backed asset in a large market outweighs the immediate dilution. The upcoming interim data for Halneuron and the start of SP16 trials provide multiple catalysts for future growth.

Keywords

Dogwood Therapeutics, SP16, Serpin Pharma, Exclusive License Agreement, Chemotherapy-Induced Peripheral Neuropathy, CIPN, Cancer Related Pain, LRP1 agonist, Halneuron, NaV1.7 inhibitor, Biotechnology, Clinical-stage, SEC filing, Equity issuance, Preferred Stock, Stockholder approval, Drug development, Pain management, Neuropathy